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Objective: Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopu-
rine drugs. Low activity phenotypes are correlated with several mutations in the TPMT
gene and adverse drug reactions. The molecular basis for dissimilar enzymatic activity 
of TPMT has been established in Caucasians, African-Americans and Southwest Asians, 
but it remains to be elucidated in Iranian population. Until present, no study on Iranian 
population has been performed on the known alleles of TPMT. The aim of this study was 
to investigate the frequencies of four of the most common variants of this gene.
Materials and Methods: This study was conducted during 2007 at the Department of He-
matology, Tarbiat Modares University, Tehran, Iran.  Using PCR-RFLP and allele specific 
PCR techniques, allelic variants of the TPMT gene TPMT*2(G238C), TPMT*3B (G460A), 
TPMT*3C (A719G) and TPMT*3A (G460A and A719G) were genotyped in a normal popu-
lation of 127 Iranians. 
Results: In this study TPMT*2 showed a prevalence of 7.08%. TPMT*3C and *3A were 
found in 2.47% and 2.18% of the samples, respectively. TPMT*3B variant was not detect-
ed in Iranian subjects. 112 out of 127 participants showed homozygote wild type allele.
Conclusion: This study is the first to analyze TPMT allele frequencies in a sample of 
Iranian population and indicates that TPMT*2 is the most common allele (7.08%) in this 
population. These results can help to organize national pretreatment strategies in patients 
with acute lympho blastic leukemia (ALL) or other diseases requiring thiopurine medication 
in their standard therapy.
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Introduction
Drug metabolizing enzymes participate in the neu-
tralization of xenobiotics and biotransformation of 
these drugs. Polymorphisms in genes coding drug-
metabolizing enzymes can alter the activity of the 
enzymes for their substrates (1). The anti-cancer 
prodrugs, 6-mercaptopurine (6-MP) and azathio-
prine (AZA), are metabolized by thiopurine S-
methyltransferase (TPMT) and widely used to treat 
several diseases such as childhood Acute Lym-
phoblastic Leukemia (ALL), autoimmune hepatitis, 
myasthenia gravis and rheumatoid arthritis (2, 3). 
Thiopurine S-methyltransferase (TPMT, MIM# 
187680) is a cytosolic enzyme that catalyzes the 
S-methylation of aromatic and heterocyclic sulf-
hydryl compounds like 6-Mercaptopurine (6MP) 
(4). The TPMT gene is localized on chromosome 
6p22.3 and consists of 10 exons. TPMT hypo ac-
tivity is inherited as an autosomal co-dominant trait 
that occurs in 1/300 of general population,   also it 
appears as homozygosity in some polymorphisms 
causing complete enzyme inactivity. About 10%
of individuals have intermediate activity because 
of heterozygosity (5, 6). Some polymorphisms of 
TPMT have been shown to interfere with normal 
optimum activity of this enzyme and cause AZA 
and 6-MP toxicity.
To avoid hematotoxicity associated with TPMT-
deficiency, phenotyping and genotyping tests 
should precede along with thiopurine therapy. 
TPMT molecular pharmacogenetic studies resulted 
in the discovery of a series of variant alleles (con-
taining single nucleotide polymorphisms; SNPs) 
associated with significantly decreased levels of 
TPMT activity (3). High TPMT activity, results in 
a greater production of inactive methylated me-
tabolites, which reduces therapeutic efficacy. Con-
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